SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-19-001474
Filing Date
2019-03-20
Accepted
2019-03-20 17:18:41
Documents
5
Period of Report
2019-04-30
Effectiveness Date
2019-03-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2238165zdef14a.htm DEF 14A 602666
2 G96470.JPG g96470.jpg GRAPHIC 15106
3 G971103.JPG g971103.jpg GRAPHIC 4111
4 G24912BGI001.GIF g24912bgi001.gif GRAPHIC 125074
5 G24912BGI002.GIF g24912bgi002.gif GRAPHIC 79174
  Complete submission text file 0001047469-19-001474.txt   911939
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 19695305
SIC: 2834 Pharmaceutical Preparations